Jove
Visualize
Contact Us

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

4.1K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.1K
Liver Physiology01:30

Liver Physiology

3.3K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

255
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
255
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.3K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

389
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
389

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The lancet. Gastroenterology & hepatology·2026
Same author

Factors affecting the quality of life of adults living with congenital adrenal hyperplasia: a qualitative study of lived experience.

Endocrine connections·2026
Same author

Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.

Diabetes care·2026
Same author

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.

Cell metabolism·2026
Same author

Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery.

Clinical endocrinology·2026
Same author

Long-Term Mortality After PCI or CABG for Left Main Stem Disease: Updated Meta-Analysis of Randomized Trials Using Reconstructed Individual-Participant Survival Data.

Journal of the American College of Cardiology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 16, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.4K

Fighting liver fat.

David Koeckerling1, Jeremy W Tomlinson2, Jeremy F Cobbold3

  • 1Medical Sciences Division, University of Oxford, Oxford, UK.

Endocrine Connections
|July 5, 2020
PubMed
Summary

Non-alcoholic fatty liver disease (NAFLD) is a growing health concern linked to metabolic syndrome. Early fibrosis detection and risk management are key to preventing progression to cirrhosis.

Keywords:
non-alcoholic fatty liver disease

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.6K

Related Experiment Videos

Last Updated: Dec 16, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.4K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.6K

Area of Science:

  • Hepatology
  • Metabolic Diseases
  • Clinical Medicine

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is a chronic liver condition strongly associated with metabolic syndrome.
  • Its clinical impact is increasing due to rising prevalence, significant cardiometabolic risks, and potential progression to cirrhosis.
  • NAFLD progression varies histologically from simple steatosis to steatohepatitis with fibrosis.

Purpose of the Study:

  • To review current concepts in NAFLD diagnosis and progression.
  • To focus on practical risk assessment and management strategies for primary and secondary care.
  • To highlight the importance of fibrosis staging in NAFLD prognosis.

Main Methods:

  • Review of current literature on NAFLD diagnosis and progression.
  • Emphasis on non-invasive methods for fibrosis staging, including composite scoring systems and transient elastography.
  • Discussion of multidisciplinary treatment approaches focusing on cardiometabolic risk factors.

Main Results:

  • Fibrosis stage is the primary prognostic factor in NAFLD.
  • Non-invasive methods are crucial for risk stratification by fibrosis stage.
  • Lifestyle and pharmacological interventions targeting cardiometabolic risk are central to management.

Conclusions:

  • Effective management of NAFLD requires accurate fibrosis assessment and risk stratification.
  • A multidisciplinary approach integrating lifestyle changes and targeted therapies is essential.
  • While liver-targeted pharmacotherapies are limited, promising agents are in development for advanced disease.